Goldman Sachs raised the firm’s price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company’s Q3 results and announced deal with Novartis (NVS) involving both a research and expanded software utilization collaboration drove the stock higher, and while operating results from the quarter came in slightly below expectations, the management relayed confidence in the forward outlook for the balance of the year for the company’s Software business, noting resiliency across large and mid-sized ACV accounts with increasing depth of utilization, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Schrodinger price target raised to $28 from $25 at BMO Capital
- Schrödinger Reports Q3 2024 Earnings and New Novartis Collaboration
- Schrodinger announces expanded license agreement with Novartis
- Schrodinger reports Q3 EPS (52c), consensus (60c)
- Schrodinger narrows FY24 software revenue growth view to 8%-13%